B
TARO

Bailard’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Bailard’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-15,000
Closed -$1.66M – 329
2016
Q3 		$1.66M Sell
15,000
-20
-0.1% -$2.65K 0.15% 130
2016
Q2 		$2.19M Buy
+15,020
New +$2.13M 0.26% 96

Other funds holding TARO

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bailard's TARO Position: Q4 2016 in Review

Bailard sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q4 2016, closing a stake of 15,000 shares — an estimated $1.66M sold.

Bailard first reported a position in TARO in Q2 2016 and held it in 2 quarters. The position peaked at $2.19M in Q2 2016. 151 funds tracked by Wall St. Rank hold TARO as of Q4 2016.

  • Bailard reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q4 2016 after selling out during the quarter.
  • Bailard sold 15,000 Taro Pharmaceutical Industries Ltd. shares in Q4 2016, an estimated $1.66M.
  • Bailard first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2016 and held it in 2 quarters.
  • Bailard's Taro Pharmaceutical Industries Ltd. position peaked at $2.19M in Q2 2016.
  • 151 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q4 2016.

Based on Bailard's 13F filing for Q4 2016, filed 10 Feb 2017.